COMMON STOCK PURCHASE WARRANT NOVUS THERAPEUTICS, INC.Novus Therapeutics, Inc. • January 16th, 2020 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ________1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Novus Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares of Common Stock (the shares of Common Stock issuable upon exercise hereof being referred to as the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
WARRANT EXERCISE AGREEMENTWarrant Exercise Agreement • January 16th, 2020 • Novus Therapeutics, Inc. • Pharmaceutical preparations
This Warrant Exercise Agreement (this “Agreement”), dated as of January [ ], 2020, is by and between Novus Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned holder (each, a “Holder” and, collectively, the “Holders”) of Series A warrants (the “Series A Warrants”) to purchase shares of common stock of the Company, par value $0.001 per share (the “Common Stock”), at an exercise price of $4.00 per share, and Series B warrants “Series B Warrants”) to purchase shares of Common Stock of the Company, at an exercise price of $4.00 per share, issued by the Company on May 2, 2019. The Series A Warrants and Series B Warrants are referred to herein, collectively, the “Original Warrants”).
